MedDRA preferred term · less active than usual

Decreased activity: adverse event reports recording this term

10,547 reports to FDA record it, 2004–2026; 0.1% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

10,547
reports recording the term: 0.1% of all reports; 613
reports, 12 months to June 2026: 711 in the 12 months before; 66.2%
marked serious by the reporter: 57.4% across all reports; 4.3%
record death among outcomes, as reported: 9.1% across all reports

10,547 reports in FDA's adverse event database record the MedDRA term "Decreased activity" (in plain words, less active than usual): 0.1% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

613 reports recorded it in the 12 months to June 2026, down 14% from 711 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 66.2% are marked serious, 4.3% include death among the outcomes and 28.7% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Entresto, Jakafi and Niraparib. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Entresto	Angiotensin 2 receptor blocker	567	0.5%
Jakafi	Janus kinase inhibitor	565	1%
Niraparib	Poly(ADP-Ribose) polymerase inhibitor	458	7.1%
Dupixent	Interleukin-4 receptor alpha antagonist	261	0.1%
Forteo	Parathyroid hormone analog	200	0.2%
Prednisone	Corticosteroid	198	0.1%
Truvada	Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	179	0.5%
Humira	—	148	0%
Atripla	—	144	0.8%
Symbicort	Corticosteroid	138	0.4%
Tiotropium bromide	Anticholinergic	130	0.2%
Zejula	Poly(ADP-Ribose) polymerase inhibitor	129	0.8%
Viread	Hepatitis B virus nucleoside analog reverse transcriptase inhibitor	108	0.5%
Novothyrox	—	106	1%
Enbrel	Tumor necrosis factor blocker	103	0%
Methotrexate	Folate analog metabolic inhibitor	92	0%
Prolia	RANK ligand inhibitor	92	0.1%
Latuda	Atypical antipsychotic	88	0.5%
Xolair	Anti-IgE	88	0.1%
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	85	0.2%
Metformin	Biguanide	85	0.1%
Opsumit	Endothelin receptor antagonist	80	0.2%
Albuterol sulfate	beta2-Adrenergic agonist	77	0.2%
Alvesco	—	76	1.7%
Venclexta	BCL-2 inhibitor	70	0.2%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0.1% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Angiotensin 2 receptor blocker	658	0.3%	0%
Janus kinase inhibitor	641	0.2%	0%
Poly(ADP-Ribose) polymerase inhibitor	618	1.2%	0.1%
Corticosteroid	614	0.1%	0%
Kinase inhibitor	517	0.1%	0%
Atypical antipsychotic	458	0.1%	0%
Prostacycline vasodilator	314	0.3%	0.3%
Interleukin-4 receptor alpha antagonist	266	0.1%	0.1%
Tumor necrosis factor blocker	258	0%	0%
Human immunodeficiency virus nucleoside analog reverse transcriptase inhibitor	220	0.3%	0%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 21.1%117

2 to 111.8%187

12 to 170.9%99

18 to 4411.2%1,183

45 to 6421.3%2,249

65 to 7412.3%1,299

75 and over11.2%1,179

Age not given40.1%4,234

Patient sex

Female51.9%5,479

Male34.5%3,642

Not given13.5%1,426

Grey bar: all 20,646,523 reports in the database. 72.1% of these reports give the United States as the country.

Questions about "Decreased activity"

What does "Decreased activity" mean in an adverse event report?

In plain language: less active than usual. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record decreased activity?

10,547 reports through June 2026 (0.1% of all reports), 613 of them in the latest 12 months.

Which drugs appear most often in these reports?

Entresto (567), Jakafi (565), Niraparib (458), Dupixent (261) and Forteo (200). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.